Prelude Therapeutics
PRLD
57 hedge funds and large institutions have $986M invested in Prelude Therapeutics in 2021 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 12 reducing their positions, and 12 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 12
3.53% more ownership
Funds ownership: 69.85% → 73.38% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5% less funds holding
Funds holding: 60 → 57 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
30% less capital invested
Capital invested by funds: $1.41B → $986M (-$423M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$23M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$14.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$10.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$9.21M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$1.54M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$1.27M |
| 3 |
Goldman Sachs
New York
|
-$886K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$845K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$790K |
PRLD Hedge Fund Activity: Q2 2021 in Review
57 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q2 2021, worth a combined $986M — down 30% from $1.41B a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PRLD and 9 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 24 added.
The largest buyer was UBS AM, adding an estimated $23M. The largest seller was HHLR Advisors, cutting an estimated $1.54M.
- 57 institutional investors held Prelude Therapeutics (PRLD) as of Q2 2021, down from 60 in Q1 2021.
- Funds reported $986M of Prelude Therapeutics stock for Q2 2021, down 30% quarter-over-quarter.
- 9 funds opened new Prelude Therapeutics positions in Q2 2021 and 12 closed out, a net change of -3 holders.
- The largest Prelude Therapeutics buyer in Q2 2021 was UBS AM, an estimated $23M added.
- The largest Prelude Therapeutics seller in Q2 2021 was HHLR Advisors, an estimated $1.54M sold.
Based on aggregated 13F filings for Q2 2021.